Territorial Availability: Available through Bertin Technologies only in France
- Synonyms
- glycyl-L-valyl-L-?-aspartyl-L-lysyl-L-alanylglycyl-L-cysteinyl-L-arginyl-L-tyrosyl-L-methionyl-L-phenylalanylglycylglycyl-L-cysteinyl-L-seryl-L-valyl-L-asparaginyl-L-?-aspartyl-L-?-aspartyl-L-cysteinyl-L-cysteinyl-L-prolyl-L-arginyl-L-leucylglycyl-L-cysteinyl-L-histidyl-L-seryl-L-leucyl-L-phenylalanyl-L-seryl-L-tyrosyl-L-cysteinyl-L-alanyl-L-tryptophyl-L-?-aspartyl-L-leucyl-L-threonyl-L-phenylalanyl-L-seryl-L-aspartic acid, cyclic (7?21),(14?26),(20?33)-tris(disulfide)
- Correlated keywords
- SNX482 CaV2.3 c-Fos Hysterocrates tarantula NK KV 1.1 1.2 1.4 SNX482
- Product Overview:
SNX-482 is a peptide originally isolated from H. gigas venom that acts as a class E/R-type voltage-sensitive calcium channel blocker (IC50 = 30 nM in 192C cells expressing human class E channels).{57113} It is selective for class E/R-type over class A and class B calcium channels (IC50s = >280 and ~800 nM, respectively), as well as the voltage-gated potassium channels Kv1.1, Kv1.2, and Kv1.4 (IC50s = >140 nM for all). SNX-482 inhibits class E/R-type calcium currents in isolated rat posterior pituitary (IC50 = 4 nM), however, it has no effect on class E/R-type calcium currents in isolated rat granule cells, retinal ganglion cells, or hippocampal pyramidal cells at concentrations up to 200 nM. Intrathecal administration of SNX-482 (0.5 µg/animal) inhibits formalin-induced neurokinin-1 (NK1) receptor internalization and cfos expression in the ipsilateral dorsal horn and reduces formalin-induced paw flinching in rats.{57114}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.